Myocardial Infarction Market Size in the 7MM was ~USD 21,750 Million in 2023 and is Expected to Show Positive Growth Through 2034, Estimates DelveInsight

DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Myocardial Infarction, historical and forecasted epidemiology as well as the MI therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Discover Key Insights into the Myocardial Infarction Market with DelveInsight's In-Depth Report @ Myocardial Infarction Treatment Market - https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Key Takeaways from the Myocardial Infarction Market Report
• The Myocardial Infarction Market Size in the 7MM was estimated to be nearly USD 21,750 million in 2023 and is expected to show positive growth through 2034. The US accounted for the largest MI market size at nearly USD 16,300 million in 2023, driven by higher case volumes and comparatively higher treatment costs.
• In September 2025, Caristo Diagnostics announced its role as global imaging core lab for Abcentra's FORTIFY clinical trial, providing coronary inflammation and plaque measurement using its proprietary CaRi-Heart and FAI-Score technologies for cardiovascular disease diagnosis and treatment.
• In June 2025, CeleCor Therapeutics finalized its rolling New Drug Application submission to the FDA for zalunfiban (Disaggpro), an investigational subcutaneous antiplatelet therapy for STEMI heart attacks. The submission follows promising Phase 3 CeleBrate trial results demonstrating that pre-hospital administration significantly reduced severe heart damage and cardiovascular complications. This Fast Track-designated small-molecule inhibitor would enable emergency responders to protect cardiac tissue at first point of medical contact if approved.
• In March 2025, Powerful Medical announced that its PMcardio STEMI AI ECG model received Breakthrough Device Designation from the US FDA, highlighting innovation in detecting STEMI and STEMI equivalents requiring urgent intervention.
• The total Myocardial Infarction diagnosed prevalent cases in the 7MM comprised approximately 15.5 million cases in 2023. The US accounted for the largest MI prevalent population at ~55% of the 7MM (~8 million cases), while EU4 and the UK accounted for ~35% and Japan ~10%.
• According to DelveInsight estimates, there were approximately 3.2 million STEMI cases and 5 million NSTEMI cases in the United States in 2023. Among EU4 and the UK, Germany had the largest number of diagnosed MI cases, while Spain had the lowest.
• Among currently approved therapies, lipid-lowering drugs generated the highest revenue in the US in 2023. Among EU4 and the UK, Germany accounted for the maximum MI market size while Spain occupied the lowest position.
• The Myocardial Infarction Companies include AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Amgen, Novartis, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, Mesoblast, and others.
• Promising MI Therapies include FARXIGA/FORXIGA (dapagliflozin; AstraZeneca; Phase III), JARDIANCE (empagliflozin; Boehringer Ingelheim/Eli Lilly; Phase III), Olpasiran (Amgen; Phase III), Pelacarsen/TQJ230 (Novartis; Phase III), Selatogrel (Idorsia Pharmaceuticals; Phase III), FDY-5301 (Faraday Pharmaceuticals; Phase III), CSL112 (CSL Behring; Phase III), IMT-358 (Immediate Therapeutics; Phase III), CL2020 (Mitsubishi Chemical Group; Phase II/III), and others.

Stay ahead in the Myocardial Infarction Therapeutics Market with DelveInsight's Strategic Report @ Myocardial Infarction Market Outlook - https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Myocardial Infarction Epidemiology Segmentation in the 7MM
The epidemiology section provides historical, current, and forecasted MI prevalence scenarios across the 7MM - covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.
• Diagnosed Prevalent Cases of Myocardial Infarction in the 7MM
• Gender-Specific Prevalence of Myocardial Infarction in the 7MM
• Type-Specific Prevalence of Myocardial Infarction (STEMI and NSTEMI) in the 7MM

Download the report to understand which factors are driving Myocardial Infarction epidemiology trends @ Myocardial Infarction Prevalence - https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Myocardial Infarction Emerging Drugs
• FARXIGA/FORXIGA (Dapagliflozin): AstraZeneca
Dapagliflozin is a first-in-class, oral, once-daily SGLT2 inhibitor currently being evaluated in the DAPA-MI Phase III trial - a first-of-its-kind registry-based randomized controlled trial in patients without type 2 diabetes following acute MI. The trial is conducted in collaboration with Uppsala Clinical Research Center and MINAP in the UK. In July 2022, AstraZeneca was granted Fast Track Designation in the US for FARXIGA's development to reduce the risk of hospitalization for heart failure or cardiovascular death following acute MI.

• Olpasiran: Amgen
Olpasiran (formerly AMG 890) is a small interfering RNA designed to lower the body's production of apolipoprotein(a) - a key component of Lp(a) associated with increased cardiovascular risk. End-of-treatment Phase II OCEAN(a)-DOSE study data were presented at the American Heart Association's Late-Breaking Science Session in November 2022, demonstrating significant Lp(a) reduction in adults with elevated Lp(a) levels and history of atherosclerotic cardiovascular disease. Olpasiran is currently in Phase III development.

• Pelacarsen (TQJ230): Novartis
Pelacarsen is an investigational antisense oligonucleotide targeting Lp(a), administered subcutaneously, designed to reduce major cardiovascular events in patients with established cardiovascular disease. It is currently in Phase III clinical evaluation and represents one of the most advanced Lp(a)-targeting therapies in the cardiovascular pipeline.

Myocardial Infarction Market Outlook
Myocardial infarction refers to ischemic necrosis of myocardial tissue, most commonly caused by coronary artery disease. Type 1 MI occurs when an unstable plaque ruptures, leading to coronary artery occlusion, while Type 2 MI results from a mismatch between oxygen supply and demand. The current treatment paradigm follows multimodal regimen strategies targeting pain relief, rapid diagnostic classification, reperfusion therapy, and long-term secondary prevention across therapeutic classes including antiplatelet agents, anticoagulants, vasodilators, beta blockers, lipid-lowering drugs, ACE inhibitors, ARBs, and calcium channel blockers.

The dynamics of the MI market are currently evolving with the recent launch of PCSK9 inhibitors and the anticipated entry of novel therapeutic classes. Key late-stage pipeline candidates including FARXIGA, JARDIANCE, olpasiran, pelacarsen, and selatogrel are expected to significantly reshape the treatment paradigm by addressing residual cardiovascular risk beyond LDL reduction, targeting Lp(a), and improving acute care through innovative delivery mechanisms. Greater integration of early patient screening, AI-assisted diagnostics, and novel cardiometabolic approaches are expected to further advance patient outcomes over the forecast period.

"The Myocardial Infarction Market Size in the 7MM was ~USD 21,750 million in 2023 and is expected to show positive growth through 2034, driven by the expected launch of FARXIGA, JARDIANCE, olpasiran, pelacarsen, and selatogrel, alongside advances in AI-driven diagnostics, novel antiplatelet therapies, and Lp(a)-targeting approaches."

Get In-Depth Knowledge on Myocardial Infarction Market Trends and Forecasts with DelveInsight @ Myocardial Infarction Treatment Drugs - https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Scope of the Myocardial Infarction Market Report
• Coverage: 7MM
• Study Period: 2020-2034
• Forecast Period: 2024-2034
• Myocardial infarction Companies: AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Amgen, Novartis, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, Mesoblast, and others
• Myocardial infarction Therapies: INSPRA, PLAVIX, BRILINTA, PRALUENT, FARXIGA, JARDIANCE, Olpasiran, Pelacarsen, Selatogrel, FDY-5301, CSL112, IMT-358, CL2020, and others
• Myocardial infarction Therapeutic Assessment: Current marketed therapies across key drug classes and emerging pipeline candidates
• Market Dynamics: Market drivers and barriers, SWOT and conjoint analysis, KOL views, and reimbursement landscape

Unlock Strategic Insights with DelveInsight's Comprehensive Myocardial Infarction Market Report @ Myocardial Infarction Market Drivers and Barriers - https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Table of Content
• Key Insights
• Report Introduction
• Executive Summary
• Key Events
• Epidemiology and Market Forecast Methodology
• Myocardial Infarction Market Overview at a Glance
• Disease Background and Overview
• Treatment and Management
• Guidelines and Recommendations for MI
• Epidemiology and Patient Population of Myocardial Infarction (MI) in the 7MM
• Patient Journey
• Marketed Therapies
• Emerging Therapies
• Myocardial Infarction (MI): 7MM Analysis
• Myocardial Infarction Unmet Needs
• SWOT Analysis
• KOL Views
• Market Access and Reimbursement
• Appendix
• DelveInsight Capabilities
• Disclaimer
• About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: kkumar@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/myocardial-infarction-market

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.